Health-Related Quality of Life in Molecular Targeted Therapy
Fig. 17.1 QOL assessments. Patients responded three times: (1) before each treatment, (2) 1 week after the first dose of cisplatin, and (3) at the end of the second course….
Screening Lung Cancer with Low-Dose CT Combined with Molecular Markers
Ref # Year published Subject Numbera Positive rate Detected Lung cancer Detection rate Ratio of Stage I [9] 1996 High risk 3457 17 % 15 0.43 % 93 % [10]…
Mechanism of Resistance to Targeted Molecular Therapy
Fig. 13.1 Mechanisms of acquired resistance to EGFR-TKI 13.2.1 The T790M Secondary Mutation Third-generation EGFR-TKIs such as osimertinib (AZD9291) and CO-1686 have shown promising activity in treatment-resistant EGFR mutation-positive NSCLCs…
Immunotherapy
Fig. 14.1 (a) Interaction of TCR and antigen only is insufficient to T-cell activation. Co-stimulator signal with CD80/86 and CD28 leads to adequate activation. (b) CTLA-4 has higher affinity than…
Minor-Driver Mutant
Gene Smoking status Histology Genetic alteration ROS1 Primarily never smokers AD ROS1 translocations RET Primarily never smokers AD RET translocations HER2 Primarily never smokers AD HER2 mutations HER2 amplification BRAF…
Gene Signature
Fig. 18.1 Therapy-targeted pathways in lung cancer Targeted therapy in lung cancer and the drugs that influence them. EGF, epidermal growth factor; TGF-α, transforming growth factor-α; EGFR, epidermal growth factor…
Companion Diagnostics
Release date Title April 2005 Draft preliminary concept paper: Drug-Diagnostic Co-development Concept Paper July 2011 Draft Guidance for Industry and Food and Drug Administration Staff: In Vitro Companion Diagnostic Devices…
Management of Adverse Effects by Molecular Targeted Therapy and Immunotherapy
Adverse event Grade 1 Grade 2 Grade 3 Grade 4 Rash acneiform Papules and/or pustules covering<10 % BSA, which may or may not be associated with symptoms of pruritus or…
Lung Cancer Complicated with Interstitial Lung Diseases
Regimen N (%) AE (N) AE (%) Carboplatin + paclitaxel 140 35.4 12 8.6 Carboplatin + etoposide 82 20.7 3 3.7 Cisplatin + etoposide 38 9.6 4 10.5 Vinorelbine 30…
ALK Mutant
© Springer Science+Business Media Singapore 2017Yuichi Takiguchi (ed.)Molecular Targeted Therapy of Lung Cancer10.1007/978-981-10-2002-5_11 11. ALK Mutant Akihiko Gemma1 (1) Division of Pulmonary Medicine, Graduate School of Medicine, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8602, Japan…
